- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05656573
CART-PSMA Cells for Advanced Prostate Cancer
Phase I Study of CART-PSMA Cells in Patients With Advanced Prostate Cancer
Study Overview
Study Type
Enrollment (Estimated)
Phase
- Phase 1
Contacts and Locations
Study Contact
- Name: Jay Zhang, MD/PhD
- Phone Number: 858-205-4558
- Email: jiezhang8@hotmail.com
Study Locations
-
-
-
Beijing, China
- Recruiting
- Chinese PLA General Hospital
-
Contact:
- Jay Zhang, MD/PhD
-
Principal Investigator:
- Xu Zhang, MD/PhD
-
Sub-Investigator:
- Haixing Mai, MD/PhD
-
Sub-Investigator:
- Yu Gao, MD/PhD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- All participants must have the ability to understand and the willingness to sign a written informed consent.
- Histologic confirmation of prostate cancer.
- Tumor expressing PSMA as demonstrated by immunohistochemistry analysis or other methods.
- Eastern Cooperative Oncology Group (ECOG) performance status 0 - 2.
- Under general air conditions, blood oxygen saturation >90%.
- Adequate liver function, specifically alanine aminotransferase (ALT) < 3 times of upper limit of normal (ULN), aspartate transferase (AST)< 3 times of ULN, serum bilirubin and alkaline phosphatase < 2 times of ULN.
- Adequate renal function, specifically serum creatinine < 2.0 mg/dl.
- Adequate cardiac function, specifically left ventricular ejection fraction (LVEF)≥50%.
- Hemoglobin concentration ≥80g/L.
- The side effects brought by the latest treatment should be recovered, and the latest chemotherapy should be at least 7 days before; At least three t½ have passed since the latest immunotherapy.
Exclusion Criteria:
- Patients with other malignant tumors or major diseases.
- Patients who are already undergoing other clinical drug trials or other gene therapy or cell therapy.
- Patients with uncontrolled active infection.
- Patients with active hepatitis B or hepatitis C infection.
- Patients with human immunodeficiency virus (HIV) infection.
- Patients who are being treated with immunosuppressive agents or systemic steroids (other than inhalation therapy).
- Patients with various types of serious heart disease or a history of severe cerebrovascular disease.
- Patients with congenital immune deficiency diseases or bone marrow deficiency diseases.
- Patients with active autoimmune disease, including connective tissue disease, uveitis, inflammatory bowel disease, or multiple sclerosis; or a history of severe (as judged by the physician-investigator) autoimmune disease requiring prolonged immunosuppressive therapy.
- Patients with active medical condition that, in the opinion of the physician-investigator, would substantially increase the risk of uncontrollable CRS (cytokine release syndrome) or CAR Neurotoxicity.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Sequential Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: autologous CART-PSMA cells
|
This study consists of 2 parts: Part A (Dose Escalation): The investigators are looking the highest dose of the study intervention that can be administered safely without severe or unmanageable side effects in participants that advanced prostate cancer. Up to 4 dosing cohorts, with up to 3 subjects enrolled in each cohort, will be explored as follows: cohort 1: CART-PSMA cells 1-3x10^7 on Day 0; cohort 2: CART-PSMA cells 1-3x10^8 on Day 0; cohort 3: CART-PSMA cells 1-3x10^7 on Day 0,following lymphodepleting chemotherapy with cyclophosphamide 300 mg/m2/day and fludarabine 30 mg/m2/day given over 3 days; cohort 4: CART-PSMA cells 1-3x10^8 on Day 0,following lymphodepleting chemotherapy with cyclophosphamide 300 mg/m2/day and fludarabine 30 mg/m2/day given over 3 days; Part B (Expansion Cohort): Participants will be treated at the respective dose (at or below the Maximum Tolerated Dose), as determined during Part A (Dose Escalation). |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Occurrence of study related adverse events, laboratory toxicities and clinical events that are possibly, likely, or definitely related to study participation.
Time Frame: Up to 15 years
|
Assessing the type, frequency, severity, and duration of adverse events as a result of CART-PSMA cell infusion via physical, laboratory and imaging examination.
|
Up to 15 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The persistence, accumulation, and migration of CART-PSMA cells.
Time Frame: Up to 2 years
|
Assessing the trafficking of CART-PSMA cells in the peripheral blood by quantifying the mRNA of CAR gene at the time of each infusion as well as at each time of follow-up blood collection.
Peripheral blood will be collected prior to the initial infusion and will be set as baseline.
|
Up to 2 years
|
Overall survival (OS)
Time Frame: Up to 15 years
|
Estimating median OS from CART-PSMA cell infusion to the event date (death) or last contact date (censor date) by Kaplan Meier methods.
|
Up to 15 years
|
Progression-free survival (PFS)
Time Frame: Up to 15 years
|
Estimating median PFS by survival without biochemical (PSA) or radiographic evidence of disease progression or relapse from CART-PSMA cell infusion to event date (progression/relapse or death); the censor date: off protocol therapy date (required disallowed treatment or withdrawal of consent for further therapy) or last contact date.
|
Up to 15 years
|
Patterns of change in PSA (prostate-specific antigen)
Time Frame: Up to 5 years
|
Assessing PSA response by the percentage of change in PSA from baseline to the defined time-frame on therapy (or earlier if patients discontinue therapy prior to the time-frame) as well as the maximum decline in PSA that occurs at any point during CART-PSMA cell infusion.
|
Up to 5 years
|
Serum cytokine profile
Time Frame: Up to 2 years
|
Assessing potential cytokine release syndrome (CRS) toxicity and CART cell effector function, sequential serum samples by analysis of Th1/Th2 cytokines (e.g., IL-2, IFNgamma, TNFalpha, IL-10, GMCSF, IL-6, MIP-1alpha) before and after CART-PSMA cell infusion.
|
Up to 2 years
|
Phenotypes and frequencies of immune cell subsets in the peripheral blood pre- and post-therapy
Time Frame: Up to 2 years
|
Assessing phenotypes and frequencies of immune cell subsets in the peripheral blood, T cell subsets and phenotypes utilising groups of labelled antibodies.
|
Up to 2 years
|
Changes in circulating tumor cells in peripheral blood
Time Frame: Up to 2 years
|
Assessing changes in levels of circulating tumor cells (CTC) to investigate if decreases in CTC levels correlate with response.
|
Up to 2 years
|
Circulating cell-free deoxyribonucleic acid (cfDNA) in peripheral blood
Time Frame: Up to 2 years
|
Assessing changes in levels of cfDNA to investigate if decreases in cfDNA levels correlate with response.
|
Up to 2 years
|
Collaborators and Investigators
Sponsor
Collaborators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- NT1921-H301-CART-PSMA
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Prostate Cancer
-
Roswell Park Cancer InstituteRecruitingObesity | Overweight | Cancer Survivor | Prostate Adenocarcinoma | Stage I Prostate Cancer | Stage II Prostate Cancer | Stage III Prostate Cancer | Stage IV Prostate Cancer | Stage IIA Prostate Cancer | Stage IIB Prostate Cancer | Stage IVA Prostate Cancer | Stage IVB Prostate Cancer | Stage A Prostate Cancer | Stage... and other conditionsUnited States
-
Sidney Kimmel Cancer Center at Thomas Jefferson...Regeneron Pharmaceuticals; Prostate Cancer FoundationWithdrawnStage III Prostate Cancer | Stage IV Prostate Cancer | Stage IVA Prostate Cancer | Stage IVB Prostate Cancer | Stage IIIA Prostate Cancer | Stage IIIB Prostate Cancer | Stage IIIC Prostate Cancer
-
Jonsson Comprehensive Cancer CenterNational Cancer Institute (NCI)CompletedRecurrent Prostate Cancer | Stage I Prostate Cancer | Stage III Prostate Cancer | Adenocarcinoma of the Prostate | Stage IV Prostate Cancer | Stage IIA Prostate Cancer | Stage IIB Prostate CancerUnited States
-
Ryan Kohlbrenner, MDRadiological Society of North AmericaCompletedProstate Adenocarcinoma | Stage IV Prostate Cancer AJCC v8 | Prostate Carcinoma | Stage IIIA Prostate Cancer AJCC v8 | Stage IIIB Prostate Cancer AJCC v8 | Stage IIC Prostate Cancer AJCC v8 | Stage III Prostate Cancer AJCC v8 | Stage IIIC Prostate Cancer AJCC v8 | Stage IVA Prostate Cancer AJCC v8 | Stage...United States
-
Jonsson Comprehensive Cancer CenterProgenics Pharmaceuticals, Inc.TerminatedRandomized Trial of PSMA PET Scan Before Definitive Radiation Therapy for Prostate Cancer (PSMA-dRT)Stage II Prostate Cancer AJCC v8 | Stage IIIA Prostate Cancer AJCC v8 | Stage IIIB Prostate Cancer AJCC v8 | Stage IIC Prostate Cancer AJCC v8 | Stage III Prostate Cancer AJCC v8 | Stage IIIC Prostate Cancer AJCC v8 | Stage IIA Prostate Cancer AJCC v8 | Stage IIB Prostate Cancer AJCC v8 | Stage I Prostate...United States
-
University of Southern CaliforniaNational Cancer Institute (NCI); SanofiTerminatedDiarrhea | Recurrent Prostate Cancer | Hormone-resistant Prostate Cancer | Stage I Prostate Cancer | Stage III Prostate Cancer | Stage IV Prostate Cancer | Stage IIA Prostate Cancer | Stage IIB Prostate CancerUnited States
-
Wake Forest University Health SciencesNational Cancer Institute (NCI)CompletedRecurrent Prostate Carcinoma | Stage I Prostate Cancer | Stage II Prostate Cancer | Hormone-Resistant Prostate Cancer | Stage IIA Prostate Cancer | Stage IIB Prostate CancerUnited States
-
Case Comprehensive Cancer CenterNational Cancer Institute (NCI)CompletedRecurrent Prostate Cancer | Stage I Prostate Cancer | Stage III Prostate Cancer | Adenocarcinoma of the Prostate | Stage IIA Prostate Cancer | Stage IIB Prostate CancerUnited States
-
Ohio State University Comprehensive Cancer CenterRiverside Methodist HospitalCompletedStage I Prostate Cancer | Stage III Prostate Cancer | Stage IV Prostate Cancer | Stage IIA Prostate Cancer | Stage IIB Prostate CancerUnited States
-
Mayo ClinicNational Cancer Institute (NCI)WithdrawnStage I Prostate Cancer AJCC v8 | Stage II Prostate Cancer AJCC v8 | Stage IIIA Prostate Cancer AJCC v8 | Stage IIIB Prostate Cancer AJCC v8 | Stage IIC Prostate Cancer AJCC v8 | Stage III Prostate Cancer AJCC v8 | Stage IIIC Prostate Cancer AJCC v8 | Stage IIA Prostate Cancer AJCC v8 | Stage IIB Prostate...United States
Clinical Trials on CART-PSMA cells
-
Bioray LaboratoriesChanghai HospitalSuspendedCastrate-Resistant Prostate CancerChina
-
Zhejiang UniversityBioray LaboratoriesCompletedCastrate-Resistant Prostate CancerChina
-
Weijia Fang, MDInnovative Cellular Therapeutics Co., Ltd.CompletedMalignant Neoplasms of Digestive OrgansChina
-
Fujian Medical UniversityUnknown
-
University of PennsylvaniaTerminated
-
Innovative Cellular Therapeutics Co., Ltd.Anhui Provincial Cancer HospitalNot yet recruiting
-
PersonGen BioTherapeutics (Suzhou) Co., Ltd.Second Affiliated Hospital of Suzhou UniversityUnknown
-
The Affiliated Hospital of the Chinese Academy...Unknown
-
The Affiliated Hospital of the Chinese Academy...UnknownLeukemia, Lymphocytic, AcuteChina
-
Fujian Medical UniversityUnknown